Palliative Care in Integrative Oncology

MacLeod, Jodi; Lopez, Gabriel; Bao, Ting

doi:10.1089/acm.2020.0269

Cited by 1 publication

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 26 In contrast to conventional oncology care, integrative oncology aims to add evidence-based complementary and alternative therapies to the daily care of patients to address their physical and mental problems and improve their quality of life. 27 …”

Section: Discussionmentioning

confidence: 99%

“…Therefore, complementary and alternative therapies have become increasingly popular for symptom control in clinical practice,25 leading to an acceleration in the development of integrative medicine 26. In contrast to conventional oncology care, integrative oncology aims to add evidence-based complementary and alternative therapies to the daily care of patients to address their physical and mental problems and improve their quality of life 27…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Fu’s subcutaneous needling for cancer pain management: protocol for a pragmatic randomised controlled trial

Xu¹,

Yu²,

Cai³

et al. 2023

BMJ Open

View full text Add to dashboard Cite

IntroductionPain is a common symptom in patients with cancer, and pain management is crucial for these patients. Fu’s subcutaneous needling (FSN) is a modern acupuncture therapy based on basic medicine commonly used in patients with pain. However, evidence of its effectiveness in treating cancer pain has not been systematically proven. Therefore, this pragmatic randomised controlled trial aims to evaluate the effectiveness and safety of FSN for cancer pain management.Methods and analysisOverall, 120 eligible patients will be recruited and randomly assigned into two groups using block randomisation. Both groups will be administered analgesic drugs according to the National Comprehensive Cancer Network guidelines. The treatment group will receive FSN therapy one time a day for 6 days. Additionally, we will assess analgesic consumption as the primary outcome and the Numerical Rating Scale, outbreak pain, symptom assessment and adverse events as secondary outcomes to evaluate the effect and safety of FSN in treating cancer pain. The incidence of adverse events will be monitored to assess the safety of FSN.Ethics and disseminationEthics approval was obtained from the Ethics Committee of the First Affiliated Hospital of Guangzhou University of Chinese Medicine (approval No: K(2021)096). The results will be published in a peer-reviewed journal, and trial participants will be informed via email and/or phone calls.Trial registration numberChiCTR2200056348.

show abstract

Section: Discussionmentioning

confidence: 99%